The economics of curing ALS

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

New analysis puts a multi-billion-dollar value on progress as Japan opens new scientific pathways for ALS discovery.

According to new research from the UK’s Office of Health Economics (OHE), the rewards of successfully treating amyotrophic lateral sclerosis (ALS) could be counted not only in lives improved but in billions of dollars saved and earned. The analysis, commissioned by Challenge Works, estimates that effective treatments for ALS could be worth around $26–40 billion in the US over a decade, with potential global value exceeding $143 billion if the disease were eradicated [1]. For a condition so rare yet so ruinous, the numbers reframe ALS as both a moral and economic imperative – a health challenge where scientific innovation and societal return are tightly entwined.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Eleanor Garth

Editor

Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

With a keen interest in all things geroscience, Eleanor covers the biological mechanisms of aging, highlighting how interventions – from nutritional strategies to advanced therapeutics – can influence the aging process at a cellular level. She also investigates the broader implications of aging research, including the integration of longevity science into healthcare strategy and the expanding wellness economy. Her work (hopefully) provides insights into how these developments are shaping the emerging landscape of healthspan optimization and age-related innovation.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Evommune bets $30m upfront on a new autoimmune drug

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE